Hybridoma technology is a method for producing monoclonal antibodies. Production: Hybridoma technology is based on the fusion of an immune cell, called a B-cell, with a cancer cell, called a myeloma cell, to create a hybrid cell line that can produce a single type of mAb. The B-cell is typically obtained from an animal that has been immunized with the target antigen. The hybridoma cells are then screened to identify those that produce the desired mAb. Applications: Hybridoma technology has a wide range of applications, including: Research: Monoclonal antibodies produced by hybridoma technology are widely used as research tools in the study of cell biology, immunology, and disease. Diagnostics: Monoclonal antibodies produced by hybridoma technology are used as reagents in diagnostic tests and assays. Therapeutics: Monoclonal antibodies produced by hybridoma technology are used as treatments for various diseases, including cancer, autoimmune diseases, and infectious diseases. Advan...